[{"id":"ff1be9d1-13a5-4b53-8202-0376c103961f","acronym":"SUNRAY-02","url":"https://clinicaltrials.gov/study/NCT06890598","created_at":"2025-06-07T14:38:17.196Z","updated_at":"2025-06-07T14:38:17.196Z","phase":"Phase 3","brief_title":"Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT06890598 - SUNRAY-02","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Imfinzi (durvalumab) • olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 03/27/2025","start_date":" 03/27/2025","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 02/01/2032","study_completion_date":" 02/01/2032","last_update_posted":"2025-06-05"},{"id":"45b9e4e8-9732-4ed9-b569-eae18917beb8","acronym":"KEYNOTE E27","url":"https://clinicaltrials.gov/study/NCT04956640","created_at":"2021-07-09T12:57:24.328Z","updated_at":"2025-02-25T16:16:26.190Z","phase":"Phase 1/2","brief_title":"Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)","source_id_and_acronym":"NCT04956640 - KEYNOTE E27","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • erlotinib • carboplatin • Tyvyt (sintilimab) • Verzenio (abemaciclib) • pemetrexed • batoprotafib (TNO155) • temuterkib (LY3214996) • LY3295668 • olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 550","initiation":"Initiation: 07/19/2021","start_date":" 07/19/2021","primary_txt":" Primary completion: 06/01/2026","primary_completion_date":" 06/01/2026","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2025-01-28"},{"id":"df4169a6-f1ec-4f63-bbe5-1c56c58e0abe","acronym":"","url":"https://clinicaltrials.gov/study/NCT06235983","created_at":"2024-02-01T16:21:05.006Z","updated_at":"2024-07-02T16:34:59.841Z","phase":"Phase 1","brief_title":"A Study of LY3537982 in Chinese Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT06235983","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/29/2024","start_date":" 02/29/2024","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2024-05-31"},{"id":"fff29023-3174-439e-bff2-887c9cbd0b7a","acronym":"SUNRAY-01","url":"https://clinicaltrials.gov/study/NCT06119581","created_at":"2023-11-07T16:14:17.558Z","updated_at":"2024-07-02T16:35:00.471Z","phase":"Phase 3","brief_title":"A Study of LY3537982 Plus Immunotherapy With or Without Chemotherapy in Participants With Non-Small Cell Lung Cancer (NSCLC) With a Change in a Gene Called KRAS G12C","source_id_and_acronym":"NCT06119581 - SUNRAY-01","lead_sponsor":"Eli Lilly and Company","biomarkers":" PD-L1 • KRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12","tags":["PD-L1 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • olomorasib (LY3537982)"],"overall_status":"Recruiting","enrollment":" Enrollment 1016","initiation":"Initiation: 12/21/2023","start_date":" 12/21/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2029","study_completion_date":" 10/01/2029","last_update_posted":"2024-05-29"}]